Serina Therapeutics Welcomes Karen J. Wilson to its Board of Directors
Serina Therapeutics (NYSE American: SER) has announced the appointment of Karen J. Wilson to its Board of Directors. Wilson brings over 30 years of leadership experience in life sciences, currently serving on the boards of Connect Biopharma Holdings, Elicio Therapeutics, and LAVA Therapeutics.
Wilson previously held senior finance positions at Jazz Pharmaceuticals, including Senior Vice President of Finance and Principal Accounting Officer. Her prior experience includes senior finance roles at PDL BioPharma, ViroLogic, and Novare Surgical Systems, as well as consulting and auditing at Deloitte & Touche LLP. She is a Certified Public Accountant with a B.S. in Business from UC Berkeley.
The company also announced the departure of Steven Mintz from its Board of Directors, who helped guide Serina's transition from private to public company.
Serina Therapeutics (NYSE American: SER) ha annunciato la nomina di Karen J. Wilson nel suo Consiglio di Amministrazione. Wilson porta oltre 30 anni di esperienza dirigenziale nelle scienze della vita, attualmente ricoprendo cariche nei consigli di Connect Biopharma Holdings, Elicio Therapeutics e LAVA Therapeutics.
Wilson ha precedentemente ricoperto posizioni senior nel settore finanziario presso Jazz Pharmaceuticals, inclusa quella di Vicepresidente Senior della Finanza e Principal Accounting Officer. La sua esperienza precedente include ruoli senior nella finanza presso PDL BioPharma, ViroLogic e Novare Surgical Systems, nonché consulenza e auditing presso Deloitte & Touche LLP. È un Commercialista Certificato con una laurea in Business presso UC Berkeley.
L'azienda ha anche annunciato l'uscita di Steven Mintz dal suo Consiglio di Amministrazione, che ha contribuito a guidare la transizione di Serina da società privata a società pubblica.
Serina Therapeutics (NYSE American: SER) ha anunciado el nombramiento de Karen J. Wilson en su Junta Directiva. Wilson aporta más de 30 años de experiencia en liderazgo en ciencias de la vida, desempeñándose actualmente en las juntas de Connect Biopharma Holdings, Elicio Therapeutics y LAVA Therapeutics.
Wilson ocupó anteriormente cargos senior en finanzas en Jazz Pharmaceuticals, incluyendo Vicepresidenta Senior de Finanzas y Principal Accounting Officer. Su experiencia previa incluye roles senior en finanzas en PDL BioPharma, ViroLogic y Novare Surgical Systems, así como consultoría y auditoría en Deloitte & Touche LLP. Es Contadora Pública Certificada con un B.S. en Negocios de UC Berkeley.
La empresa también anunció la salida de Steven Mintz de su Junta Directiva, quien ayudó a guiar la transición de Serina de empresa privada a pública.
세리나 테라퓨틱스 (NYSE American: SER)는 카렌 J. 윌슨을 이사회의 일원으로 임명했다고 발표했습니다. 윌슨은 생명 과학 분야에서 30년 이상의 리더십 경험을 보유하고 있으며, 현재 Connect Biopharma Holdings, Elicio Therapeutics 및 LAVA Therapeutics의 이사회에서 활동하고 있습니다.
윌슨은 Jazz Pharmaceuticals에서 재무 담당 수석 부사장 및 주요 회계 책임자를 포함한 고위 재무직을 역임했습니다. 그녀의 이전 경험에는 PDL BioPharma, ViroLogic, Novare Surgical Systems에서의 고위 재무 역할과 Deloitte & Touche LLP에서의 컨설팅 및 감사가 포함됩니다. 그녀는 UC 버클리에서 경영학 학사 학위를 받은 공인 회계사입니다.
회사는 또한 사의 이사회에서 스티븐 민츠가 물러난 사실을 발표했으며, 그는 세리나가 개인 기업에서 상장 기업으로 전환하는 과정에서 도움을 주었습니다.
Serina Therapeutics (NYSE American: SER) a annoncé la nomination de Karen J. Wilson à son Conseil d'Administration. Wilson apporte plus de 30 ans d'expérience en leadership dans les sciences de la vie, servant actuellement au sein des conseils de Connect Biopharma Holdings, Elicio Therapeutics et LAVA Therapeutics.
Wilson a précédemment occupé des postes financiers seniors chez Jazz Pharmaceuticals, y compris celui de Vice-présidente Senior des Finances et de Principal Accounting Officer. Son expérience antérieure comprend des rôles financiers seniors chez PDL BioPharma, ViroLogic et Novare Surgical Systems, ainsi que du conseil et de l'audit chez Deloitte & Touche LLP. Elle est Comptable Agréée avec un B.S. en commerce de l'UC Berkeley.
L'entreprise a également annoncé le départ de Steven Mintz de son Conseil d'Administration, qui a aidé à guider la transition de Serina d'une entreprise privée à une entreprise publique.
Serina Therapeutics (NYSE American: SER) hat die Ernennung von Karen J. Wilson in den Vorstand bekannt gegeben. Wilson bringt über 30 Jahre Führungserfahrung im Bereich der Lebenswissenschaften mit und ist derzeit Mitglied der Aufsichtsräte von Connect Biopharma Holdings, Elicio Therapeutics und LAVA Therapeutics.
Wilson hatte zuvor leitende Finanzpositionen bei Jazz Pharmaceuticals inne, darunter die des Senior Vice President of Finance und Principal Accounting Officer. Ihre frühere Erfahrung umfasst auch leitende Finanzrollen bei PDL BioPharma, ViroLogic und Novare Surgical Systems sowie Beratung und Prüfung bei Deloitte & Touche LLP. Sie ist eine staatlich geprüfte Wirtschaftsprüferin mit einem B.S. in Betriebswirtschaft von der UC Berkeley.
Das Unternehmen gab außerdem die Abberufung von Steven Mintz aus dem Vorstand bekannt, der zur Umwandlung von Serina von einem privaten zu einem öffentlichen Unternehmen beigetragen hat.
- Appointment of experienced board member with over 30 years of life sciences sector expertise
- New director brings significant financial and accounting expertise from senior roles at major biotech companies
- Addition of active board member with current positions in multiple biotech companies
- None.
HUNTSVILLE, AL, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Karen J. Wilson to the Board of Directors.
"We are excited to welcome Karen to the Board of Directors. Karen’s financial expertise and deep understanding of the biotech landscape will play a crucial role in guiding our strategic initiatives and delivering transformative therapies to patients,” said Steve Ledger, Serina’s Chief Executive Officer.
Ms. Wilson brings over three decades of leadership experiences in the life sciences sector. She currently serves as a board director for Connect Biopharma Holdings Limited, Elicio Therapeutics, Inc. and LAVA Therapeutics N.V. Previously, she held the position of Senior Vice President of Finance at Jazz Pharmaceuticals plc, where she also served as Principal Accounting Officer and Vice President of Finance. Prior to joining the Jazz Pharmaceuticals organization in February 2011, she held senior finance roles at PDL BioPharma, ViroLogic, and Novare Surgical Systems and was a consultant and auditor for Deloitte & Touche LLP. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley.
Ms. Wilson stated, "I am excited to join Serina at such a pivotal time in its growth. I look forward to working with the talented executive team and fellow board members to help drive the company's vision forward and make a meaningful impact in the lives of patients."
Serina also announced the departure of Steven Mintz from its Board of Directors. Mr. Ledger stated, “We thank Steven for his contributions to Serina’s transition from private to public company and our positioning for future growth.”
About the POZ Platform™
Serina’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but may be limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.
Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTM provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
For more information, please visit https://serinatherapeutics.com.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2023, the company’s Current Report on Form 8-K that was filed with the SEC on April 1, 2024, and the company’s other periodic reports and documents filed from time to time with the SEC.
The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley sriley@serinatherapeutics.com
(256) 327-9630
FAQ
Who is Karen J. Wilson and what is her role at Serina Therapeutics (SER)?
What are Karen Wilson's current board positions besides Serina Therapeutics (SER)?
What was Karen Wilson's previous role at Jazz Pharmaceuticals before joining SER's board?
Who left Serina Therapeutics' (SER) board following Karen Wilson's appointment?
